Kennedy's Proposal Targets BPC-157 and Other Compounds Pending FDA Rule
Health and Human Services Secretary Robert F. Kennedy Jr. filed a draft policy on Wednesday that would permit compounding pharmacies to prepare six specific peptide drugs, even though the Food and Drug Administration (FDA) has not approved them for safety or effectiveness. The policy targets BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, substances currently marketed for wellness purposes…
Read original article on PravdaReport →Related news
-
Russia’s Battlegroup South destroys 52 Ukrainian UAV control posts over past 24 hours
War & Defense
Armed Conflict
Ukraine
-
Europe struggles to reach 75% gas storage capacity despite increased LNG imports
Economy
Trade
Europe
-
Singapore Food Agency recalls Bomberry chocolate-covered fruit over metal contamination
Health
Public Health
Singapore
-
Russian stocks up as main trading session opens
Economy
Markets
Russia
-
Convoy carrying humanitarian aid heads to Alyoshki in Kherson Region
International
Foreign Aid
Ukraine
-
Why Kale Tastes Sweeter After Frost
Culture & Lifestyle
Food
-
HHS Grants Enforcement Discretion for Six Peptides in 503A Compounding Pharmacies
Health
Pharma
United States
-
Former DEA Agent Alleges Leadership Allowed Fentanyl to Circulate in New Mexico for Larger Cases
Crime & Justice
Law Enforcement
United States